Miragen Therapeutics Inc (NQ: MGEN )
23.03 USD -1.90 (-7.62%) Official Closing Price Updated: 7:58 PM EST, Jan 15, 2021 Add to My Watchlist
Press releases about Miragen Therapeutics Inc
miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease
December 17, 2020
miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
November 10, 2020
Thinking about buying stock in Miragen Therapeutics, Trevena, Norwegian Cruise Line, American Resources, or Delta Air Lines?
October 30, 2020
Thinking about buying stock in Miragen Therapeutics, Nio, Scholar Rock, General Electric, or Boeing?
October 28, 2020
miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL)
October 05, 2020
miRagen Announces Leadership Transition and Review of Strategic Alternatives
September 14, 2020
miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL
August 20, 2020
Stochastic K% D% Indicates Bullish US Stocks: $CIDM $STM $MGEN
August 04, 2020
Tags The Market Signal
From The Market Signal
miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics
July 28, 2020
Thinking about buying stock in Miragen Therapeutics, ChannelAdvisor, Northern Dynasty Minerals, Tiziana Life Sciences, or Tonix Pharmaceuticals?
July 24, 2020
Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma
July 23, 2020
Thinking about buying stock in New Age Beverages, Lexicon Pharmaceuticals, Miragen Therapeutics, Opko Health, or Niu Technologies?
July 21, 2020
miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary Fibrosis
June 22, 2020
Thinking about buying stock in Virgin Galactic, Miragen Therapeutics, Nantkwest Inc, Agenus Inc, or Norwegian Cruise Line?
June 22, 2020
miRagen Strengthens Leadership Team with Appointment of Lee Rauch as Chief Operating Officer
June 18, 2020
Thinking about buying stock in Energous Corp, Miragen Therapeutics, Hertz, Kopin Corp, or MGM Resorts?
June 17, 2020
miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd
June 16, 2020
miRagen to announce encouraging new preclinical safety and efficacy data for MRG-229 in IPF on June 22nd; and provide an update on the development program during the KOL call
miRagen Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 11, 2020
February 20, 2020
miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock
February 07, 2020
miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
February 06, 2020